SynthesisWorld journal of surgical oncology2025
Prognostic value of lymphocyte-to-monocyte ratio in patients with small cell lung cancer: a meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lymphocyte-to-monocyte ratio (LMR) has been previously analyzed for its value in forecasting prognostic outcomes in patients with small cell lung cancer (SCLC); however, the findings remain conflicting. Therefore, we performed this meta-analysis to identify LMR's precise role of the LMR in predicting the prognosis of SCLC.
methodsWe searched PubMed, Embase, Web of Science, and the Cochrane Library until April 10, 2025, and evaluated function of LMR in forecasting SCLC prognosis by determining aggregated hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsNine articles involving 1701 cases included in the present study. As revealed by our pooled data, decreased LMR showed close relation to poor overall survival (OS) (HR = 1.49, 95% CI = 1.16-1.91, p = 0.002) and inferior progression-free survival (PFS) (HR = 1.77, 95% CI = 1.16-2.70, p < 0.001) in SCLC. As indicated by subgroup analysis, prominent prognostic value of the LMR for OS remained unaffected by sample size, study center, or threshold point (p < 0.05), and that for PFS remained unaffected by country (p < 0.05). The stability of the results was also verified using sensitivity and publication-bias analyses.
conclusionAccording to our findings, LMR is markedly related to dismal OS and inferior PFS of patients with SCLC. Thus, LMR can serve as a candidate prognostic marker for SCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.